Synthesis and evaluation of potent and selective β3 adrenergic receptor agonists containing heterobiaryl carboxylic acids

被引：20
作者：
Shearer, Barry G. [1 ]
Chao, Esther Y.
Uehling, David E.
Deaton, David N.
Cowan, Conrad
Sherman, Bryan W.
Milliken, Tula
Faison, Walter
Brown, Kathleen
Adkison, Kimberly K.
Lee, Frank
机构：
[1] GlaxoSmithKline Inc, Dept Med Chem, Res Triangle Pk, NC 27709 USA
[2] GlaxoSmithKline Inc, Dept Receptor Biol, Res Triangle Pk, NC 27709 USA
[3] GlaxoSmithKline Inc, Dept Pharmacol, Res Triangle Pk, NC 27709 USA
[4] GlaxoSmithKline Inc, Dept Res Bioanal & Drug Metab, Res Triangle Pk, NC 27709 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2007年 / 17卷 / 16期
关键词：
beta(3) adrenergic receptor; agonist; selective; diabetes;
D O I：
10.1016/j.bmcl.2007.05.069
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The design, synthesis, and SAR of a novel series of heterobiaryl phenethanolamine beta(3) adrenergic receptor agonists are described. The furan analogue 49 was shown to elicit a significant dose-dependent lowering of plasma glucose in a rodent model of type 2 diabetes. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码：4670 / 4677
页数：8
相关论文
共 31 条
  • [1] METABOLIC ALTERATIONS ASSOCIATED WITH THE ANTIDIABETIC EFFECT OF BETA(3)-ADRENERGIC RECEPTOR AGONISTS IN OBESE MICE
    ARBEENY, CM
    MEYERS, DS
    HILLYER, DE
    BERGQUIST, KE
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1995, 268 (04): : E678 - E684
  • [2] SELECTIVE REDUCTION OF AROMATIC NITRO-COMPOUNDS WITH STANNOUS CHLORIDE IN NON-ACIDIC AND NON-AQUEOUS MEDIUM
    BELLAMY, FD
    OU, K
    [J]. TETRAHEDRON LETTERS, 1984, 25 (08) : 839 - 842
  • [3] DISODIUM (R,R)-5-[2-[[2-(3-CHLOROPHENYL)-2-HYDROXYETHYL]AMINO]PROPYL]-1,3-BENZODIOXOLE-2,2-DICARBOXYLATE (CL 316,243) - A POTENT BETA-ADRENERGIC AGONIST VIRTUALLY SPECIFIC FOR BETA-3 RECEPTORS - A PROMISING ANTIDIABETIC AND ANTIOBESITY AGENT
    BLOOM, JD
    DUTIA, MD
    JOHNSON, BD
    WISSNER, A
    BURNS, MG
    LARGIS, EE
    DOLAN, JA
    CLAUS, TH
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (16) : 3081 - 3084
  • [4] Drug treatment of obesity: from past failures to future successes?
    Collins, P
    Williams, G
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (01) : 13 - 25
  • [5] MOLECULAR CHARACTERIZATION OF THE HUMAN BETA-3-ADRENERGIC RECEPTOR
    EMORINE, LJ
    MARULLO, S
    BRIENDSUTREN, MM
    PATEY, G
    TATE, K
    DELAVIERKLUTCHKO, C
    STROSBERG, AD
    [J]. SCIENCE, 1989, 245 (4922) : 1118 - 1121
  • [6] A selective human β3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys
    Fisher, MH
    Amend, AM
    Bach, TJ
    Barker, JM
    Brady, EJ
    Candelore, MR
    Carroll, D
    Cascieri, MA
    Chiu, SHL
    Deng, LP
    Forrest, MJ
    Hegarty-Friscino, B
    Guan, XM
    Hom, GJ
    Hutchins, JE
    Kelly, LJ
    Mathvink, RJ
    Metzger, JM
    Miller, RR
    Ok, HO
    Parmee, ER
    Saperstein, R
    Strader, CD
    Stearns, RA
    Thompson, GM
    Tota, L
    Vicario, PP
    Weber, AE
    Woods, JW
    Wyvratt, MJ
    Zafian, PT
    MacIntyre, DE
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (11) : 2387 - 2393
  • [7] FOXTON MW, 1995, Patent No. 9533724
  • [8] GRANNEMAN JG, 1992, MOL PHARMACOL, V42, P964
  • [9] GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895
  • [10] Himms-Hagen J., 1996, CURR OPIN ENDOCRINOL, V3, P59
1234